» Articles » PMID: 28280053

Copeptin Associates with Cause-Specific Mortality in Patients with Impaired Renal Function: Results from the LURIC and the 4D Study

Overview
Journal Clin Chem
Specialty Biochemistry
Date 2017 Mar 11
PMID 28280053
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In chronic kidney disease (CKD) arginine vasopressin (AVP) cannot efficiently act via renal V2-receptors. AVP is upregulated leading to augmented activation of V1a- and V1b-receptors, which might contribute to the increase in cardiovascular and infectious complications in CKD. Here, we evaluate copeptin, a surrogate of AVP, and its association with cause specific mortality among patients within the whole spectrum of renal function.

Methods: Copeptin was measured in baseline samples from the LURIC (n = 3131 patients with coronary angiograms) and the 4D-Study (n = 1241 type 2 diabetic hemodialysis patients). Patients were stratified into 4 groups: estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m, 60-89 mL/min/1.73 m, <60 mL/min/1.73 m, and hemodialysis. The association of copeptin with mortality was assessed by Cox proportional hazards regression during 9.9 years of median follow-up in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study and 4 years of median follow-up in the German Diabetes Dialysis Study (4D-Study).

Results: Median copeptin increased with decreasing eGFR: 5.6 [interquartile range (IQR), 3.1-8.1] pmol/L (eGFR ≥90 mL/min/1.73 m), 6.7 (2.9-10.5) pmol/L (eGFR 60-89 mL/min/1.73 m), 15.3 (6.7-23.9) pmol/L (eGFR <60 mL/min/1.73 m), and 80.8 (51.2-122) pmol/L (hemodialysis), respectively. Per SD increase in copeptin, the risk of coronary, infectious, and all-cause mortality increased by 25, 30, and 15% [hazard ratios (HR), 1.25; 95% CI, 1.13-1.39; HR, 1.30; 95% CI, 0.98-1.71; and HR, 1.15; 95% CI, 1.05-1.25], respectively, in patients with eGFR 60-89 mL/min/1.73 m. Except for coronary death, results were similar among patients with more advanced renal disease. No significant association was found in patients with normal renal function.

Conclusions: Copeptin concentrations were independently associated with coronary, infectious, and all-cause mortality in patients with renal impairment. In patients with normal renal function no significant association was found.

Citing Articles

Fibroblast growth factor 23 but not copeptin is independently associated with kidney failure and mortality in patients with chronic kidney disease.

Michon-Colin A, Metzger M, Bankir L, Gauci C, Brunel M, Baron S Clin Kidney J. 2023; 16(12):2472-2481.

PMID: 38046034 PMC: 10689138. DOI: 10.1093/ckj/sfad149.


Copeptin, Natriuretic Peptides, and Cardiovascular Outcomes in Patients With CKD: The German Chronic Kidney Disease (GCKD) Study.

Schneider M, Schmid M, Nadal J, Krane V, Saritas T, Busch M Kidney Med. 2023; 5(11):100725.

PMID: 37915964 PMC: 10616426. DOI: 10.1016/j.xkme.2023.100725.


The role of copeptin in kidney disease.

Iglesias P, Silvestre R, Fernandez-Reyes M, Diez J Endocrine. 2022; 79(3):420-429.

PMID: 36242751 DOI: 10.1007/s12020-022-03219-0.


Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty liver disease incidence.

Tong C, Li Q, Kong L, Ni X, Halengbieke A, Zhang S J Endocrinol Invest. 2022; 45(12):2233-2245.

PMID: 35896944 DOI: 10.1007/s40618-022-01848-w.


Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.

Velho G, Ragot S, El Boustany R, Saulnier P, Fraty M, Mohammedi K Cardiovasc Diabetol. 2018; 17(1):110.

PMID: 30071874 PMC: 6071392. DOI: 10.1186/s12933-018-0753-5.